Retinoic Acid-Guided Hematopoietic Stem Cell Generation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing human hematopoietic stem cells (HSCs) face challenges in efficiently generating sufficient numbers for therapeutic applications, particularly due to the inability to discriminate between distinct progenitor populations, leading to difficulties in understanding their physiological relevance and functional behavior.

Innovation Solution

An in vitro platform is developed to produce definitive hemogenic endothelium through stage-specific, retinoic acid-dependent differentiation of pluripotent stem cells, identifying two distinct mesodermal subsets that give rise to hematopoietic progenitors, one in an RA-independent and the other in a RA-dependent manner, mimicking primary fetal endothelium.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional methods are used to produce hematopoietic stem cells, then production can proceed with standard protocols, but the ability to discriminate between distinct progenitor populations is lost and functional behavior cannot be properly understood

Engineering Contradiction:

Improvediscrimination between progenitor populationsVSAvoiddifferentiation protocol complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The differentiation protocol is segmented into distinct stages (mesoderm formation, hemogenic endothelium specification, and hematopoietic progenitor generation), with each stage characterized by specific marker expression patterns. This segmentation enables discrimination between distinct progenitor populations by defining unique molecular signatures at each developmental stage.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by identifying specific subsets of mesodermal cells with distinct properties (e.g., Tg2+ versus Tg2- populations) that give rise to different hematopoietic lineages. By characterizing the unique properties of each subset, the method enables precise discrimination and targeted manipulation of specific progenitor populations.

Inventive Principle:

Principle #3Local quality

2Productivity

If standard production methods are used, then existing protocols can be maintained, but sufficient numbers of functional HSCs for therapeutic applications cannot be generated

Engineering Contradiction:

Improvenumber of functional HSCs producedVSAvoidfunctional behavior recapitulation

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The method employs preliminary actions by pre-specifying mesodermal subsets with defined transcriptional programs before committing them to hematopoietic differentiation. By identifying and isolating specific progenitor populations (e.g., Tg+CD34- cells) at early stages, the protocol ensures that subsequent differentiation yields sufficient numbers of functional HSCs with reliable therapeutic potential.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent utilizes parameter changes by modulating differentiation conditions (growth factors, cytokines, culture conditions) at specific stages to optimize the generation of functional HSCs. By adjusting these parameters based on the identified progenitor subsets, the method achieves both high productivity and reliable functional behavior.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250333701A1Compositions and methods for generating hematopoietic stem cells (HSCS)

Publication Date: 2025.10.30 FOND AZIONE TELETHON

AI summary

The present disclosure provides methods for generating hematopoietic progenitor cells. In some embodiments, the methods involve an in vitro or ex vivo cell culture model utilizing rentionic acid signaling for producing hematopoietic progenitor cells from pluripotent stem cells.